OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104

NEXT STORY
Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress
PREV STORY
Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director

author_avatar
NASDAQ Market News

American Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention

ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) -- American Gene Technologies International Inc. (AGT), ...

author_avatar
NASDAQ Market News

AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites

author_avatar
NASDAQ Market News